ITERUM THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.61 USD | +0.62% |
|
+1.90% | -18.27% |
| Apr. 29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
| Mar. 28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
Presenter SpeechLouise Barrett (Executives)Good morning, and welcome to Iterum Therapeutics' F...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.61
USD
Average target price
6.5
USD
Spread / Average Target
+303.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.27% | 26.65M | |
| +23.37% | 47.02B | |
| +50.07% | 41.86B | |
| -0.94% | 41.76B | |
| -4.32% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Transcript : Iterum Therapeutics plc, Q1 2021 Earnings Call, May 14, 2021